Simplicity
-
Publication: CARMELINA Elderly Subgroup Analysis [1]
Review the long-term safety profile of Trajenta® among age groups.
-
Publication: CAROLINA Asian Subgroup Analysis [2]
Review the long-term safety profile of Trajenta® in Asian patients.
-
-
10 Years of Simplicity
Browse through an interactive infographic showcasing the clinical development and significant accomplishments for Trajenta®.
Trajenta®(linagliptin)
Simple. Every Day.3-6
When a DPP4i is needed for T2D management, it may be difficult to select the most appropriate therapeutic for your patient.7 With Trajenta®, it's simple every day, thanks to proven efficacy, a demonstrated long-term CV and kidney safety profile, and the convenience of always one dose, once daily. That is why physicians worldwide have valued their experience with Trajenta® across a broad range of T2D patients, for nearly 10 years. Altogether, this confidence has driven more than 21 million patient-years of exposure to Trajenta®.10
Proven Efficacy.3
Measuring HbA1c is a common measure for observing and treating patients with type 2 diabetes. When you decide to use a DPP4i to lower HbA1c, you should rely on one with proven efficacy. Trajenta® consistently lowers HbA1c for a broad range of T2D patients, and does so at a single dose, once daily. Pooled analysis of data from more than 2,200 subjects in three 24-week phase III, randomised, placebo-controlled studies shows that Trajenta® drives a placebo-corrected reduction* of 0.8% in HbA1c.
Robust CVOT Program.4-5,8-9
Trajenta® is backed by one of the most robust CVOT programs among DPP4i. The CARMELINA and CAROLINA studies included a diverse patient population of more than 13,000 T2D patients. The Trajenta® CVOT program encompassed patients with relatively early T2D as well as more severe patients with established CV and/or kidney disease.
One Dose. Always.
Whether your patient is 50 years old and recently diagnosed, or 80 years old and living with type 2 diabetes for many years, they may need one or more drugs such as a DPP4i to manage their type 2 diabetes. When they do, you may want a DPP4i that does not need to be dose adjusted as your patient ages, experiences change in weight, liver or kidney function. Trajenta® is the only globally-available DPP4i that doesn’t need to be dose adjusted, ever.†,6
Key Information
-
Indication
Trajenta® is a prescription medicine for the treatment of adults with type 2 diabetes mellitus. -
Active Ingredient
The active ingredient in Trajenta® is linagliptin, which is a dipeptidyl peptidase-4 inhibitor (DPP4i). -
Dosage & Administration
Trajenta® is available as an oral tablet in a single, 5mg dose. -
Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Resource Center
Videos. Infographics. Publications. We have an assortment of resources that you may find valuable in learning more about Trajenta® and how its Simplicity can help you in your daily management of type 2 diabetes patients.
Expand your knowledgeFootnotes
CV: cardiovascular; CVOT: cardiovascular outcome trial; DPP4i: dipeptidyl peptidase-4 inhibitor; T2D: type 2 diabetes
* Pooled analysis of data from 2,258 subjects in three 24-week phase III, randomised, placebo-controlled, parallel-group studies, who received oral linagliptin (5 mg/day) or placebo as monotherapy, added-on to metformin, or added-on to metformin plus sulphonylurea was performed. Adjusted mean HbA1c change from baseline with linagliptin was -1.2% (vs -0.4% with placebo, p<0.0001).3
† Indicated for use in adult patients. Trajenta® is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.
References
- 1. Cooper M, et al. Diabetes Obes Metab. 2020; 1–12.
- 2. Kadowaki T, et al. Diabetol Int. 2020. doi.org/10.1007/s13340-020-00447-5.
- 3. Del Prato S, et al. J Diab Compl. 2013;27:274–9.
- 4. Rosenstock J, et al. JAMA. 2019;321:69-79.
- 5. Rosenstock J, et al. JAMA. 2019; doi:10.1001/jama.2019.13772.
- 6. Trajenta® EMA Summary of Product Characteristics, October 2019.
- 7. Davies M, et al. Diabetologia. 2018;61:2461-98.
- 8. Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
- 9. Marx N, et al. Diab Vasc Res. 2015;12:164-74.
- 10.Boehringer Ingelheim, Data on File, 2019.